Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Katrien Van Roosbroeck, Francesca Fanini, Tetsuro Setoyama, Cristina Ivan, Cristian Rodriguez‐Aguayo, Enrique Fuentes‐Mattei, Lianchun Xiao, Ivan Vannini, Roxana S. Redis, Lucilla D’Abundo, Xinna Zhang, Milena S. Nicoloso, Simona Rossi, Vianey González-Villasana, Rajesha Rupaimoole, Manuela Ferracin, Fortunato Morabito, Antonino Neri, Peter P. Ruvolo, Vivian Ruvolo, Chad V. Pecot, Dino Amadori, Lynne V. Abruzzo, Steliana Calin, Xuemei Wang, M. James You, Alessandra Ferrajoli, Robert Z. Orlowski, William Plunkett, Tara M. Lichtenberg, Ramana V. Davuluri, Ioana Berindan‐Neagoe, Massimo Negrini, Ignacio I. Wistuba, Hagop M. Kantarjian, Anil K. Sood, Gabriel Lopez‐Berestein, Michael J. Keating, Muller Fabbri, George A. CălinClinical 2016 · DOI

Abstract

<b>Purpose:</b> The oncogenic miR-155 is upregulated in many human cancers, and its expression is increased in more aggressive and therapy-resistant tumors, but the molecular mechanisms underlying miR-155-induced therapy resistance are not fully understood. The main objectives of this study were to determine the role of miR-155 in resistance to chemotherapy and to evaluate anti-miR-155 treatment to chemosensitize tumors.<b>Experimental Design:</b> We performed <i>in vitro</i> studies on cell lines to investigate the role of miR-155 in therapy resistance. To assess the effects of miR-155 inhibition on chemoresistance, we used an <i>in vivo</i> orthotopic lung cancer model of athymic nude mice, which we treated with anti-miR-155 alone or in combination with chemotherapy. To analyze the association of miR-155 expression and the combination of miR-155 and <i>TP53</i> expression with cancer survival, we studied 956 patients with lung cancer, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.<b>Results:</b> We demonstrate that miR-155 induces resistance to multiple chemotherapeutic agents <i>in vitro</i>, and that downregulation of miR-155 successfully resensitizes tumors to chemotherapy <i>in vivo</i> We show that anti-miR-155-DOPC can be considered non-toxic <i>in vivo</i> We further demonstrate that miR-155 and <i>TP53</i> are linked in a negative feedback mechanism and that a combination of high expression of miR-155 and low expression of <i>TP53</i> is significantly associated with shorter survival in lung cancer.<b>Conclusions:</b> Our findings support the existence of an miR-155/TP53 feedback loop, which is involved in resistance to chemotherapy and which can be specifically targeted to overcome drug resistance, an important cause of cancer-related death. <i>Clin Cancer Res; 23(11); 2891-904. ©2016 AACR</i>.
BibTeX
@inproceedings{roosbroeck2016combining,
  author = {Katrien Van Roosbroeck and Francesca Fanini and Tetsuro Setoyama and Cristina Ivan and Cristian Rodriguez‐Aguayo and Enrique Fuentes‐Mattei and Lianchun Xiao and Ivan Vannini and Roxana S. Redis and Lucilla D’Abundo and Xinna Zhang and Milena S. Nicoloso and Simona Rossi and Vianey González-Villasana and Rajesha Rupaimoole and Manuela Ferracin and Fortunato Morabito and Antonino Neri and Peter P. Ruvolo and Vivian Ruvolo and Chad V. Pecot and Dino Amadori and Lynne V. Abruzzo and Steliana Calin and Xuemei Wang and M. James You and Alessandra Ferrajoli and Robert Z. Orlowski and William Plunkett and Tara M. Lichtenberg and Ramana V. Davuluri and Ioana Berindan‐Neagoe and Massimo Negrini and Ignacio I. Wistuba and Hagop M. Kantarjian and Anil K. Sood and Gabriel Lopez‐Berestein and Michael J. Keating and Muller Fabbri and George A. Călin},
  title = {{Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers}},
  booktitle = {Clinical},
  year = {2016},
  doi = {10.1158/1078-0432.ccr-16-1025},
}

Loading related content...

Figure